Insmed announces positive topline results from phase 3 arise study of arikayce® (amikacin liposome inhalation suspension) in patients with ntm lung disease caused by mac

—qol-b respiratory domain shown to work effectively as patient-reported outcome tool in patients with mac lung disease; to be proposed to fda as primary endpoint in encore with no modifications— —patients treated with arikayce plus macrolide-based background regimen had meaningfully larger improvements in qol-b respiratory score with strong trend toward significance vs. macrolide-based background regimen alone—  —arikayce-treated patients had nominally statistically significantly higher culture conversion rates at month 7 vs.
INSM Ratings Summary
INSM Quant Ranking